GlassScriptPhysician profile
Jasleen Singh
NPI 1700271830
$45,752.39
in general payments reported to CMS, 2019-2025
18 companies · $37K in 2025
The $37K reported for 2025 was more than what 89% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.96 · 2020: $193 · 2021: $14.91 · 2022: $678 · 2023: $1,285 · 2024: $6,268 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $4,279 · Travel and Lodging: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,366.50 |
| Food and Beverage | $4,278.91 |
| Travel and Lodging | $1,124.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $39,404.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $3,285.99 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $1,706.29 | 2022-2025 | Vemlidy, Livdelzi |
| Glaxosmithkline, LLC. | $207.48 | 2024 | |
| Abbvie INC. | $163.12 | 2019-2023 | Mavyret |
| Mirum Pharmaceuticals, INC. | $136.39 | 2023 | Livmarli |
| Sequana Medical US INC. | $133.86 | 2025 | Alfapump System |
| Orphalan INC | $127.66 | 2023 | Cuvrior |
| Qol Medical, LLC | $121.55 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $115.58 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.63 | 2020 | |
| Alnylam Pharmaceuticals INC. | $46.53 | 2023-2025 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $42.73 | 2024 | Livtencity |
| Medtronic, INC. | $22.36 | 2023 | Mazor X System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.38 | 2023 | Xifaxan |
| Alkermes, INC. | $16.29 | 2025 | Vivitrol |
| Allergan, INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasleen Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.